Sirolimus as combination rescue therapy with tumor necrosis alpha inhibitors for severe, refractory hidradenitis suppurativa - 10/10/20
Doi : 10.1016/j.jaad.2020.06.042
Thomas Bettuzzi, MD a, Laure Frumholtz, MD a, Marie Jachiet, MD a, Clémence Lepelletier, MD a, Mourad Djermane, MPH a, Florence Cordoliani, MD a, Anne Saussine, MD a, Jean-David Bouaziz, MD, PhD a, Hervé Bachelez, MD, PhD a, b, c, ⁎ 
a Department of Dermatology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
b Université de Paris, Paris, France
c Laboratory of Genetics of Skin Diseases, Unité Mixte de Recherche (UMR) Inserm U1163, Institut Imagine, Paris, France
∗Correspondence to: Hervé Bachelez, MD, PhD, Service de Dermatologie, Hôpital Saint Louis, 1 avenue Claude Vellefaux, 75475 Paris cedex 10, FranceService de DermatologieHôpital Saint Louis1 avenue Claude VellefauxParis cedex 1075475France
| Funding sources: None. |
|
| Disclosure: Dr Bachelez has served on the advisory boards of AbbVie, Almirall, Amgen, Baxalta, Biocad, Boehringer Ingelheim, Celgene, Dermavant, Eli Lilly, Leo Pharma, Janssen, Mylan, Novartis, Pfizer, Sun Pharmaceuticals, and UCB; has served as a speaker for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Leo Pharma, Janssen, Novartis, Pfizer, and UCB; has served as a consultant for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Kyowa-Kirin, Leo Pharma, Novartis, Pfizer, and UCB; and has received grant support from Boehringer Ingelheim, Leo Pharma, and Pfizer. Drs Bettuzzi, Frumholtz, Jachiet, and Lepelletier, Author Djermane, and Drs Cordoliani, Saussine, and Bouaziz have no conflicts of interest to declare. |
|
| IRB approval status: This study was conducted in compliance with the Good Clinical Practice protocol and the Declaration of Helsinki principles and was approved by local ethics committee, who waived the requirement for informed consent (authorisation number: 20190923104020). |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 5
P. 1441-1444 - novembre 2020 Retour au numéro
Article précédent
- Wound eversion versus planar closure for wounds on the face or neck: A randomized split-wound comparative effectiveness trial
- Claire C. Alexanian, Anne R. Zhuang, Milene K. Crispin, April W. Armstrong, Daniel B. Eisen
- Clinically significant incidental findings among teledermatology patients with history of skin cancer
- Marissa L.H. Baranowski, Salma de la Feld, Howa Yeung, Suephy C. Chen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?